Metastatic hormone sensitive prostate cancer
Conditions
Interventions
ADT+Rezvilutamide:N/A
Sponsors
The First Affiliated Hospital of Ningbo University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years; 2. Diagnosed with mHSPC; 3. Has used ADT and is receiving enzalutamide treatment during the hormone-sensitive phase; 4. Can be combined with docetaxel chemotherapy; 5. Can undergo local treatments such as radiotherapy or surgery; 6. In the mHSPC phase, switched to enzalutamide treatment due to other drug side effects while the tumor has not progressed.
Exclusion criteria
Exclusion criteria: 1. The patient's pathological results suggest neuroendocrine prostate cancer, among others. 2. Patients with no metastases detected on imaging; if there is lymph node metastasis, it is confined to the pelvic lymph nodes. 3. Patients with mCRPC; 4. Use of relugolix due to progression on other second-generation drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostate-specific antigen; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Biochemistry; | — |
Countries
China
Contacts
Public ContactQi Ma
The First Affiliated Hospital of Ningbo University
Outcome results
None listed